A1 Refereed original research article in a scientific journal
Finnish-Enriched SLC26A7 Variant in Congenital Hypothyroidism: Clinical Spectrum, Thyroid Histopathology, and Expression Analysis
Authors: Niuro, Laura; Ojala, Johanna; Ravi, Rowmika; Melnyk, Vladyslav; Linnossuo, Veli; Palmu, Sofia; Jännäri, Meeri; Tyystjärvi, Sofia; Löf, Christoffer; Patyra, Konrad; Makkonen, Kristiina; Jääskeläinen, Jarmo; Danner, Emmi; Huopio, Hanna; Niinikoski, Harri; Viikari, Liisa; Kero, Andreina; Miettinen, Päivi; Schoenmakers, Nadia; FinnGen, FinnGen; Reeve, Mary Pat; Kero, Jukka
Publication year: 2026
Journal: Thyroid
Volume: 36
Issue: 2
First page : 141
Last page: 152
ISSN: 1050-7256
eISSN: 1557-9077
DOI: https://doi.org/10.1177/10507256251411983
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Partially Open Access publication channel
Web address : https://doi.org/10.1177/10507256251411983
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/508861015
Self-archived copy's licence: CC BY NC
Self-archived copy's version: Publisher`s PDF
Background:
Defects in thyroid hormone synthesis at birth lead to congenital hypothyroidism (CH). Recently, pathogenic variants in the SLC26A7 gene have been linked to dyshormonogenetic goitrous CH. This anion transporter is highly expressed in the thyroid and is involved in thyroid hormone synthesis; however, its exact function and cellular localization remain unclear. In this study, we investigated SLC26A7 variants in Finnish patients with CH, characterized the phenotypes, and analyzed thyroid-specific gene expression.
Methods:SLC26A7 variants were identified from a clinical CH cohort (n = 139) using exome sequencing, and the FinnGen database (R12 release) was screened for disease associations. Thyroid histology and thyroid-specific gene expression were analyzed in six human samples (including two homozygous SLC26A7 pathogenic variant carriers, patients with goitrous and hyperactive thyroids, and normal controls) and in thyroids from different mouse models (including hypo- and hyperthyroid mice, thyroid-specific G-protein deficient, and Slc26a7-knockout mice).
Results:Four CH patients from four novel families carried the homozygous SLC26A7 (c.1893delT, p.F631Lfs*8) pathogenic variant. Two had large trachea-compressing goiters, requiring thyroidectomy already at birth. In addition, one homozygous participant with normal CH screening results developed hypothyroidism at age 16, and one patient with heterozygous SLC26A7 pathogenic variant had permanent CH at birth. Dentofacial abnormalities were frequently noted, including enamel hypoplasia (in four carriers), pro- or retrognathia, and malocclusion requiring orthodontic treatment (in 8/24 carriers). Thyrocyte hypertrophy with large colloid aggregates was a hallmark of homozygous patients. FinnGen screening revealed a 75-fold enrichment of the variant in the Finnish population, identifying a few other homozygous and seven heterozygous cases with early-onset hypothyroidism and dentofacial abnormalities. In human thyrocytes, SLC26A7 was localized to the basolateral membrane, with intense staining in hyperthyroid samples, while in mouse thyroid models, its expression pattern depended on dietary iodide levels, thyrotropin signaling, and GNAS activity.
Conclusions:We describe variable phenotypes associated with the SLC26A7 pathogenic variant, ranging from severe CH with large congenital goiters to delayed onset hypothyroidism and dentofacial abnormalities. SLC26A7 shows thyrotropin-, GNAS-, and dietary iodine-dependent basolateral localization, suggesting their role in phenotypic variations.
Downloadable publication This is an electronic reprint of the original article. |
Funding information in the publication:
This study was supported by grants from the Finnish Pediatric Foundation (J.K. no. 190001), grant from Turku University Hospital (J.K. no. 13527), Sigrid Juselius Foundation (J.K. 12/2022), Jalmari and Rauha Ahokas Foundation, Novo Nordisk Foundation (J.K. no. 0078329), Doctoral Programme in Clinical Research (DPCR) (K.M.), and Drug Research Doctoral Programme (DRDP) (V.M.) of University of Turku. N.S. is funded by the Wellcome Trust (Senior Fellowship 219496/Z/19/Z) and NIHR Cambridge Biomedical Research Centre. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH.
There is no funding information to declare for this study for L.N., J.O., V.L., S.P., M.J., S.T., C.L., K.P., J.J., E.D., H.H., H.N., L.V., A.K., P.M., F.F., and M.P.R.